Menu

Email
PR@pulnovomed.com
LinkedIn
Wechat Official Account

Pulnovo Medical Limited

Pulnovo Medical Limited

Is a globally recognized device pioneer in the treatment for heart failure. Established in 2013 and rooted in innovation, Pulnovo Medical is committed to leveraging our deep expertise in the science of breakthrough technologie with the goal to market our innovative therapeutic solutions and benefit patients around the world.

2013

Company was founded with the vision of improving patients' resilience to life

2014

First human trial for PADN initated

2015

PADN1 phaseⅡ demonstrated that in a high-risk patient population, PADN was safe and effective in reducing PAP and improving 6MWD and was associated with favorable clinical outcomes throughout the 1-year follow-up

2016

Obtained the Invention Patents in Japan, South Korea, China and other countries

2017

PADN was approved by China for innovative medical devices

2018

Carried out multi-center, randomized, blinded, sham operation clinical trials and completed the first case enrollment

2019

Obtained the Invention Patents in Japan, Europe and other countries

2020

PADN Won the Science and Technology Award of Jiangsu Province

2021

PADN granted FDA Breakthrough device desigation in only 16 days

2022

PADN Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH

PIPELINE

PIPELINE

PIPELINE

PADN

A GLOBAL FIRST-IN-CLASS DEVICE

PIPELINE

Multi-pole Pulmonary Artery RF Ablation Catheter PADN for pulmonary artery ablation

RESPONSIBILITY

FOR PATIENTS

FOR HEALTHCARE <br>PROFESSIONALS

WALKING WITH PATIENTS

TO IMPROVE PATIENTS' RESILIENCE TO LIFE

PROVIDE VALUE-BASED BREAKTHROUGH THERAPIES

TO SOLVE UNMET CLINICAL NEEDS IN PULMONARY HYPERTESION AND HEART FAILURE

FOR PATIENTS

FOR HEALTHCARE
PROFESSIONALS

NEWS

Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker

Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker

28 March

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hyperten

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hyperten

28 February

Pulnovo Medical will be attending JPM Healthcare Conference 2023

Pulnovo Medical will be attending JPM Healthcare Conference 2023

24 December

Pulnovo Medical Concludes Successful the First Steering Committee Meeting

Pulnovo Medical Concludes Successful the First Steering Committee Meeting

08 September

Take a Step

INVESTOR RELATIONS